Carolyn A Staton1, Nicola J Brown, Malcolm Wr Reed. 1. University of Sheffield, School of Medicine and Biomedical Sciences, Microcirculation Research Group, Academic Unit of Surgical Oncology, Beech Hill Road, Sheffield, South Yorkshire, S10 2RX, UK +44 (0)114 226 5852 ; +44 (0)114 271 3314 ; c.a.staton@sheffield.ac.uk.
Abstract
BACKGROUND: Angiogenesis is essential for tumour growth and development and since the pioneering work of Judah Folkman several anti-angiogenic strategies have now been successfully employed. OBJECTIVE: This article aims to present a detailed review of current knowledge of the main pathways involved in angiogenesis, the strategies employed for inhibition and the current status of angiogenesis inhibitors in therapeutic use. METHODS: A systematic review of the literature was undertaken including angiogenesis in cancer and angiogenesis inhibitors in pre-clinical and clinical trials. CONCLUSION: While angiogenic inhibitors are now in clinical use, their limited benefits mean we must urgently develop strategies to improve the efficacy of this approach.
BACKGROUND: Angiogenesis is essential for tumour growth and development and since the pioneering work of Judah Folkman several anti-angiogenic strategies have now been successfully employed. OBJECTIVE: This article aims to present a detailed review of current knowledge of the main pathways involved in angiogenesis, the strategies employed for inhibition and the current status of angiogenesis inhibitors in therapeutic use. METHODS: A systematic review of the literature was undertaken including angiogenesis in cancer and angiogenesis inhibitors in pre-clinical and clinical trials. CONCLUSION: While angiogenic inhibitors are now in clinical use, their limited benefits mean we must urgently develop strategies to improve the efficacy of this approach.
Authors: Beverly A Teicher; Rebecca G Bagley; Cecile Rouleau; Ariel Kruger; Yi Ren; Leslie Kurtzberg Journal: Ann Saudi Med Date: 2011 Mar-Apr Impact factor: 1.526
Authors: Loiy E Ahmed Hassan; Saad S Dahham; Sultan Ayesh Mohammed Saghir; Abdelhafeez M A Mohammed; Nagla M Eltayeb; Amin Malik Shah Abdul Majid; Aman Shah Abdul Majid Journal: BMC Complement Altern Med Date: 2016-10-19 Impact factor: 3.659